Results 111 to 120 of about 5,544 (172)

Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled Trial. [PDF]

ACR Open Rheumatol
Yu Y, Xue Y, Hu J, Zhang N, Li R, Guo H, Qian L, Gou W, Yang J, Mao L, Yu J, Liu S, Xu Q, Luo T, Zou H.   +14 more
europepmc   +1 more source

Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database. [PDF]

Rheumatol Ther
Padnick-Silver L, Concoff A, Gao HY, Fu Q, LaMoreaux B, Edwards NL.   +5 more
europepmc   +1 more source

Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial Emulations. [PDF]

Arthritis Rheumatol
Yokose C, McCormick N, Lu N, Jiang B, Tan K, Chigurupati S, Rai SK, Challener G, Aviña-Zubieta JA, Cipolletta E, Abhishek A, Gaffo A, Januzzi JL, Zhang Y, Choi HK.   +14 more
europepmc   +1 more source

A single-centre experience of febuxostat as a second-line urate-lowering therapy. [PDF]

Malays Fam Physician, 2021
Ong SG, Ding HJ.
europepmc   +1 more source

Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares. [PDF]

Rheumatology (Oxford)
Russell MD, Ameyaw-Kyeremeh L, Dell'Accio F, Lapham H, Head N, Stovin C, Patel V, Clarke BD, Nagra D, Alveyn E, Adas MA, Bechman K, de la Puente MA, Ellis B, Byrne C, Patel R, Rutherford AI, Cantle F, Norton S, Roddy E, Hudson J, Cope AP, Galloway JB.   +22 more
europepmc   +1 more source

Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study. [PDF]

Rheumatology (Oxford)
Uhlig T, Karoliussen LF, Sexton J, Provan SA, Haavardsholm EA, Dalbeth N, Hammer HB.   +6 more
europepmc   +1 more source

Quantitative Assessment of Baseline Serum HDL-C to Predict Gout Flares During Urate-Lowering Therapy Initiation: A Prospective Cohort Study. [PDF]

J Inflamm Res
Jiang C, Li M, Chen Y, He Y, Li X, Cui L, Qi H, Cheng Z, Zhang X, Li C, Lu J.   +10 more
europepmc   +1 more source

Correction to "Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis". [PDF]

ACR Open Rheumatol
europepmc   +1 more source

Baseline Dual-Energy Computed Tomography Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Urate-Lowering Therapy. [PDF]

Arthritis Care Res (Hoboken)
Tabi-Amponsah AD, Stewart S, Gamble G, Doyle AJ, Billington K, Son CN, Latto K, Stamp LK, Taylor WJ, Horne A, Dalbeth N.   +10 more
europepmc   +1 more source

Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators. [PDF]

Sci Rep
Sanchez C, Campeau A, Liu-Bryan R, Mikuls TR, O'Dell JR, Gonzalez DJ, Terkeltaub R.   +6 more
europepmc   +1 more source